International vaccine news excites market
The S&P/NZX 50 Index rose 32.20 points, or 0.3 percent, to 10,790.14. Within the index, 35 stocks rose, eight fell and seven were unchanged. Turnover was $124.8 million.
Data from a study of eight healthy adults suggested a vaccine under development by American biotechnology company, Moderna Inc, is safe and produces antibodies which fend off the virus.
The data is a hopeful sign, but a doctor from Johns Hopkins Center for Health Security warned the limited trial was designed to test the safety, not the efficacy, of the vaccine.
Mark Lister, head of private wealth research at Craigs Investment Partners, said New Zealand shares were “following in the footsteps” of international markets albeit more modestly.
Click the button below to subscribe and will have free unlimited access for a limited time to full article and all other articles on the site.
You will also be able to comment on articles on Good Returns.